BioCentury
ARTICLE | Company News

Merck, PeptiDream to develop macrocycles

May 2, 2015 12:50 AM UTC

Merck & Co. Inc. (NYSE:MRK) and PeptiDream Inc. (Tokyo:4587) have partnered to use the biotech's Peptide Discovery Platform System (PDPS) to generate macrocycles against multiple undisclosed targets selected by Merck.

Merck will have the right to develop and commercialize the macrocycles, and has an option to non-exclusively license the PDPS technology. PeptiDream will receive an upfront payment and research funding, and is eligible for preclinical and clinical development milestones, plus royalties. Merck spokesperson Ian McConnell declined to disclose financial details or disease areas included in the deal. ...